Evogene Ltd.

4.55+0.1600+3.64%Vol 1.85M1Y Perf 337.14%
Apr 13th, 2021 16:00 DELAYED
BID4.51 ASK4.82
Open4.85 Previous Close4.39
Pre-Market- After-Market4.64
 - -  0.09 1.98%
Target Price
15.00 
Analyst Rating
— 0.00
Potential %
229.67 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.29
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     53.52
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap117.16M 
Earnings Rating
Buy
Price Range Ratio 52W %
39.08 
Earnings Date
25th May 2021

Today's Price Range

4.424.95

52W Range

0.900010.24

5 Year PE Ratio Range

-7.40-3.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.21%
1 Month
-18.60%
3 Months
-23.53%
6 Months
19.74%
1 Year
337.14%
3 Years
48.21%
5 Years
-34.91%
10 Years
-

TickerPriceChg.Chg.%
EVGN4.550.16003.64
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
5.20
5.40
0.03
0.05
-109.40
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
44.80
-2 950.10
-2 606.10
-1 431.30
-
RevenueValueIndustryS&P 500US Markets
965.00K
0.02
-22.23
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020--0.25-
Q03 2020--0.17-
Q02 2020--0.16-
Q01 2020--0.24-
Q04 2019--0.24-
Q03 2019--0.16-
Q02 2019--0.16-
Q01 2019--0.15-
Earnings Per EndEstimateRevision %Trend
3/2018 QR-0.190.00-
6/2018 QR-0.190.00-
12/2021 FY-0.72-4.35Negative
12/2021 FY-0.71--
Next Report Date25th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.85M
Shares Outstanding25.75M
Trades Count9.09K
Dollar Volume11.29M
Avg. Volume1.63M
Avg. Weekly Volume680.72K
Avg. Monthly Volume844.06K
Avg. Quarterly Volume1.56M

Evogene Ltd. (NASDAQ: EVGN) stock closed at 4.55 per share at the end of the most recent trading day (a 3.64% change compared to the prior day closing price) with a volume of 1.85M shares and market capitalization of 117.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 139 people. Evogene Ltd. CEO is Ofer Haviv.

The one-year performance of Evogene Ltd. stock is 337.14%, while year-to-date (YTD) performance is -3.19%. EVGN stock has a five-year performance of -34.91%. Its 52-week range is between 0.9 and 10.24, which gives EVGN stock a 52-week price range ratio of 39.08%

Evogene Ltd. currently has a PE ratio of -5.90, a price-to-book (PB) ratio of 4.27, a price-to-sale (PS) ratio of 194.74, a price to cashflow ratio of 81.70, a PEG ratio of 2.32, a ROA of -31.25%, a ROC of -38.16% and a ROE of -46.45%. The company’s profit margin is -%, its EBITDA margin is -2 606.10%, and its revenue ttm is $965.00 Thousand , which makes it $0.02 revenue per share.

Of the last four earnings reports from Evogene Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Evogene Ltd.’s next earnings report date is 25th May 2021.

The consensus rating of Wall Street analysts for Evogene Ltd. is (0), with a target price of $15, which is +229.67% compared to the current price. The earnings rating for Evogene Ltd. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evogene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evogene Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.82, ATR14 : 0.84, CCI20 : -61.63, Chaikin Money Flow : -0.27, MACD : -0.68, Money Flow Index : 41.06, ROC : -1.52, RSI : 40.07, STOCH (14,3) : 31.71, STOCH RSI : 1.00, UO : 38.00, Williams %R : -68.29), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evogene Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Hold
3.00

Evogene Ltd.

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

CEO: Ofer Haviv

Telephone: +972 89311900

Address: 13 Gad Feinstein Street, Rehovot 7612002, , IL

Number of employees: 139

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

47%53%

Bearish Bullish

63%37%

News

Stocktwits